In a 67-year-old woman with melanoma receiving immune checkpoint inhibitors who now has diplopia, proximal weakness, renal impairment, lymphocytic CSF and is refractory to high-dose IV steroids after stopping the agents, what is the most appropriate next step in management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board

Educational purpose only • Exercise caution as content is pending human review

Article Review Status

Submitted

Under Review

Approved

Last updated: February 14, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Related Questions

What is the treatment for abdominal pain with checkpoint inhibitor-induced colitis?

Is certirizine (antihistamine) and famotidine (H2 receptor antagonist) effective for treating checkpoint inhibitor-induced colitis?

What is the treatment for checkpoint (immune checkpoint) colitis?

What is the initial management for checkpoint inhibitor (CI) colitis?

What is the management approach for a patient with a pathology report showing chronic active colitis, increased crypt apoptosis, and a slight increase of eosinophils in lamina propria, suggestive of mycophenolate (Cellcept) injury?

What is the recommended diagnosis and management for transverse and sigmoid sinus thrombosis?

Is oral semaglutide (Rybelsus) approved for weight loss?

In a COPD patient eligible for triple inhaled therapy, what is the reduction in mortality risk with fluticasone furoate/umeclidinium/vilanterol (VFU) compared to budesonide/glycopyrrolate/formoterol (GFB) triple therapy?

What is the recommended evaluation and management for a 47-year-old woman with a mixed hepatocellular‑cholestatic liver enzyme pattern (elevated alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, and gamma‑glutamyl transferase)?

What findings should I expect on lung auscultation in a patient with pneumonia?

What is the reduction in the annualized rate of moderate‑to‑severe COPD exacerbations with fluticasone furoate + umeclidinium + vilanterol (VFU) compared to glycopyrrolate + budesonide + formoterol (GFB) triple therapy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.